-
12:15:17 PM

REVB Stock News

10/02/23 9:00 AM
Nasdaq : REVB
managementlow float
Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors
Revelation Biosciences Inc., a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced the appointment of Lakhmir Chawla M.D. to the Company’ s Board of Directors. “We are excited to welcome Dr. Chawla as an independent director to our Board,” said James Rolke, Chief...
RHEA-AI
neutral
08/11/23 4:10 PM
Nasdaq : REVB
earningslow float
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023
Revelation’ s net cash used for operating activities for the six months ended June 30, 2023 was $3.6 million compared to net cash used for operating activities of $8.5 million for the same period in 2022. Revelation’ s net loss for the three months ended June 30, 2023 was $1.4 million, or $0.25 basic and diluted net loss per share, compared to a net loss of $1.8 million,...
RHEA-AI
negative
06/29/23 9:00 AM
Nasdaq : REVB
low float
REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders
Revelation Biosciences Inc., a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reminded stockholders that the virtual Annual Meeting of Stockholders is scheduled for Friday, July 7, 2023, at 1:00 p.m. Eastern Time and urges all stockholders to vote now.
RHEA-AI
neutral
06/12/23 4:15 PM
Nasdaq : REVB
low float
Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal
Revelation Biosciences Inc., a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that the Company has adjourned its 2023 Annual Meeting of Stockholders originally scheduled to be held on June 9, 2023, to July 7, 2023, at 1:00 p.m., Eastern Time, or at such other...
RHEA-AI
neutral
05/22/23 9:00 AM
Nasdaq : REVB
earningslow float
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress
As of March 31, 2023, Revelation had $17.7 million in cash and cash equivalents, compared to $5.3 million as of December 31, 2022. Revelation’ s net cash used for operating activities for the three months ended March 31, 2023 was $1.6 million compared to net cash used for operating activities of $4.8 million for the same period in 2022. Revelation’ s net income for...
RHEA-AI
neutral
03/30/23 5:42 PM
Nasdaq : REVB
earningslow float
Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress
Revelation Biosciences Inc., a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today reported its year end 2022 financial results and highlighted recent corporate progress. Revelation’ s net loss for the three and twelve months ended December 31, 2022 was $1.2 million and...
RHEA-AI
neutral
03/13/23 9:00 AM
Nasdaq : REVB
managementlow float
Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board
Revelation Biosciences Inc., a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, today announced it has appointed Julia Bohannon, Ph.D. and Antonio Hernandez, M.D. to its scientific advisory board. Dr. Hernandez and Dr. Bohannon are inventors of the phosphorylated hexaacyl...
RHEA-AI
neutral
03/06/23 9:00 AM
Nasdaq : REVB
conferenceslow float
Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference
Revelation Biosciences Inc., a life sciences company that is focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 to be held at The Ritz...
RHEA-AI
neutral